Cefazolin Dosing for Dialysis Patients
For hemodialysis patients with serious infections, administer cefazolin 20 mg/kg IV (rounded to nearest 500 mg increment) after each dialysis session; for peritoneal dialysis patients, use 15 mg/kg intraperitoneally once daily with a 6-hour dwell time.
Hemodialysis Patients
For Serious Infections (Catheter-Related Bloodstream Infections)
Dosing regimen: 20 mg/kg IV after each dialysis session 1
- Round to the nearest 500 mg increment (typical range: 1-2 g)
- Administer immediately post-dialysis to avoid premature drug removal
- This provides adequate coverage for methicillin-susceptible Staphylococcus aureus (MSSA) in settings with low MRSA prevalence
Timing rationale: Cefazolin is significantly cleared during hemodialysis (half-life drops from ~26 hours off dialysis to ~3 hours during dialysis) 2. Post-dialysis administration ensures:
- Adequate drug exposure between sessions
- Facilitates directly observed therapy (3 times weekly dosing)
- Predialysis trough concentrations remain 2.5× above MIC breakpoints 3
Clinical evidence: Studies demonstrate predialysis cefazolin concentrations of 41-70 mg/L with this regimen—well above the 16 mg/L MIC breakpoint for susceptible organisms 3. A recent 2024 study confirmed that 2 g three-times-weekly post-dialysis achieves 99.7% probability of target attainment for MSSA infections 4.
Alternative Considerations
Lower dose option: 1 g three-times-weekly post-dialysis may be considered for patients <50 kg or less severe infections, though this provides a lower probability of target attainment (95.4%) 4, 2.
When to use cefazolin vs. vancomycin: Cefazolin should be the first-line choice in hemodialysis units with low MRSA prevalence (<10-15%) 1. Switch from empiric vancomycin to cefazolin once MSSA is confirmed 1. This approach:
- Reduces vancomycin-resistant enterococcus development
- Provides equivalent or superior efficacy for MSSA
- Maintains similar ease of dosing
Prophylaxis Dosing
For surgical prophylaxis in hemodialysis patients, standard perioperative dosing applies (1-2 g pre-incision), but consider supplemental dosing if surgery extends beyond 4 hours or occurs >24 hours after last dialysis session.
Peritoneal Dialysis Patients
For Peritonitis Treatment
Dosing regimen: 15 mg/kg intraperitoneally once daily 5, 6
- Mix in one exchange bag
- Allow 6-hour dwell time minimum
- Can be administered in overnight dwell for automated peritoneal dialysis (APD) patients
Important distinction between antibiotics: Cefazolin maintains therapeutic concentrations throughout a 24-hour dosing interval with once-daily dosing, unlike cefalothin which shows subtherapeutic levels between doses 6. This makes cefazolin the preferred first-generation cephalosporin for peritoneal dialysis.
Pharmacokinetic considerations:
- Bioavailability exceeds 92% with intraperitoneal administration 6
- Maintains plasma concentrations >56 mg/L and dialysate concentrations >37 mg/L throughout dosing interval
- Half-life: ~10.7 hours on cycler, ~23 hours off cycler 5
Alternative Route
Intravenous administration: 15 mg/kg IV once daily can be used if intraperitoneal route is contraindicated 5. This achieves adequate serum and dialysate concentrations for 24 hours.
Critical Caveats
Residual renal function: The FDA label recommends dose adjustments for creatinine clearance 11-34 mL/min (half usual dose every 12 hours) and <10 mL/min (half usual dose every 18-24 hours) 7. However, these recommendations apply to patients NOT on dialysis. For anuric dialysis patients, follow the post-dialysis dosing regimens above.
Duration of therapy:
- Uncomplicated catheter-related infections: 2-3 weeks if catheter removed, symptoms resolve within 2-3 days, and no metastatic infection 1
- Persistent bacteremia >72 hours: 4-6 weeks 1
- Complicated infections (endocarditis, osteomyelitis): 6-8 weeks 1
Antibiotic lock therapy: For retained hemodialysis catheters, add cefazolin 5.0 mg/mL antibiotic lock solution (mixed with 2500-5000 IU/mL heparin) after each dialysis session for 10-14 days as adjunctive therapy 1.
Monitoring: While therapeutic drug monitoring is not routinely required for cefazolin, consider it in patients with:
- Prolonged time on hemodialysis (>6 months may require adjustment) 4
- Significant residual renal function
- Treatment failure or persistent infection
Do not reduce doses in dialysis patients based on standard renal dosing charts—dialysis effectively removes the drug, and concentration-dependent bactericidal activity requires adequate peak concentrations 8.